Ritter Pharmaceuticals (RTTR) Stock Price, News & Analysis

Company Overview

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $3.90 to $4.16
• 50-Day Range: $0.45 to $4.09
• 52-Week Range: $0.15 to $1.27
• Volume: 30,713 shs
• Average Volume: 14.23 million shs
• Market Capitalization: $180.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RTTR Stock Analysis - Frequently Asked Questions

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its earnings results on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01.

When did Ritter Pharmaceuticals' stock split?

Ritter Pharmaceuticals's stock reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Ritter Pharmaceuticals IPO?

Ritter Pharmaceuticals (RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), APA (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA) and Hudson Technologies (HDSN).

Company Calendar

• Last Earnings: 5/01/2020
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RTTR
• CUSIP: N/A
• CIK: 1460702
• Web: www.ritterpharmaceuticals.com
• Phone: 310-203-1000
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,130,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -162.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.67
• Quick Ratio: 3.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: 39.00

Miscellaneous

• Outstanding Shares: 46,153,000
• Free Float: N/A
• Market Cap: $180.00 million
• Optionable: Not Optionable
• Beta: -0.43